Recent Analyst Forecasts and Stock Ratings
Contineum Therapeutics, Inc. Class A Common Stock FAQ's
Contineum Therapeutics, Inc. Class A Common Stock has been rated by research analysts at Robert W. Baird, RBC Capital, Stifel Nicolaus in the past 90 days.